股本结构
单位：万股
| 公告日期 | 2025-11-05 | 2025-10-27 | 2025-11-05 | 2025-09-10 | 2025-08-08 | 2025-08-08 |
|---|---|---|---|---|---|---|
| 证券总股本 | 8743.67 | 7529.37 | 2514.64 | 2244.97 | 1140.84 | 795.99 |
| 普通股本 | 8743.67 | 7529.37 | 2514.64 | 2244.97 | 1140.84 | 795.99 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-10-31 | 2025-10-27 | 2025-09-30 | 2025-08-13 | 2025-08-04 | 2025-06-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-05 | 8743.67 | 未披露 | 定期报告 | 2025-10-31 |
| 2025-10-27 | 7529.37 | 未披露 |
更多>>
Common Stock offered 52,844,000 shares by the company
|
2025-10-27 |
| 2025-11-05 | 2514.64 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Sale of common stock, net of issuance costs
Vesting of restricted stock units
Exercise of pre-funded warrants
|
2025-09-30 |
| 2025-09-10 | 2244.97 | 未披露 | 定期报告 | 2025-08-13 |
| 2025-08-08 | 1140.84 | 未披露 | 定期报告 | 2025-08-04 |
| 2025-08-08 | 795.99 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Proceeds from the sale of common stock, less discounts
Issuance of common stock under employee stock purchase plan
Vesting of restricted stock units
|
2025-06-30 |
| 2025-05-01 | 578.87 | 未披露 |
更多>>
a one-for-thirty reverse stock split of the company’s Common Stock
|
2025-04-28 |
| 2025-04-24 | 17360.00 | 未披露 | 定期报告 | 2025-04-24 |
| 2025-03-24 | 17366.24 | 未披露 | 定期报告 | 2025-03-13 |
| 2025-03-26 | 17094.69 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock under employee stock purchase plan
Vesting of restricted stock units
|
2024-12-31 |
| 2024-11-13 | 17054.65 | 未披露 | 定期报告 | 2024-11-11 |
| 2024-11-13 | 16851.13 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Vesting of restricted stock units
|
2024-09-30 |
| 2024-08-08 | 16849.95 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-08-08 | 16819.62 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of shares of common stock under employee stock purchase plan
Vesting of restricted stock units
|
2024-06-30 |
| 2024-03-21 | 16793.78 | 未披露 | 定期报告 | 2024-03-18 |
| 2024-03-21 | 16743.46 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common stock, warrants and prefunded warrants for the purchase of common stock, net of issuance costs of $4.6 million
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
Exercise of stock options and warrants
Issuance of shares of common stock under employee stock purchase plan
|
2023-12-31 |
| 2023-11-09 | 16729.12 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-09 | 16470.57 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercise of stock options and warrants
Vesting of restricted stock units
|
2023-09-30 |
| 2023-08-10 | 16442.49 | 未披露 | 定期报告 | 2023-08-07 |
| 2023-08-10 | 16441.80 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of stock options and warrants
Issuance of shares of common stock under employee stock purchase plan
Issuance of common stock and prefunded warrants in private placement equity transaction, net of issuance costs
Vesting of restricted stock units
|
2023-06-30 |
| 2023-06-09 | 15868.49 | 未披露 | 定期报告 | 2023-05-19 |
| 2023-05-04 | 12220.75 | 未披露 | 定期报告 | 2023-05-01 |
| 2023-04-25 | 12120.75 | 未披露 | 定期报告 | 2023-04-18 |
| 2023-03-21 | 12220.75 | 未披露 | 定期报告 | 2023-03-15 |
| 2023-03-21 | 12166.73 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock, warrants and prefunded warrants for the purchase of common stock, net of issuance costs of $4.7 million
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
Exercise of warrants and prefunded warrants
Issuance of shares of common stock under employee stock purchase plan
|
2022-12-31 |
| 2022-12-09 | 12153.51 | 未披露 |
更多>>
Common stock offered 52,300,000 shares by the company
|
2022-12-09 |
| 2022-11-03 | 6923.51 | 未披露 | 定期报告 | 2022-10-31 |
| 2022-11-03 | 6873.46 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $1,004
Vesting of restricted stock units
|
2022-09-30 |
| 2022-07-29 | 6864.61 | 未披露 | 定期报告 | 2022-07-15 |
| 2022-07-19 | 6882.77 | 未披露 |
更多>>
1.37,649,086 shares issued on July 6, 2022 as stated in the Purchase Agreement
|
2022-07-06 |
| 2022-08-04 | 3099.12 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of shares of common stock under employee stock purchase plan
Vesting of restricted stock units
|
2022-06-30 |
| 2022-04-25 | 3082.36 | 未披露 | 定期报告 | 2022-04-11 |
| 2022-05-12 | 3080.95 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $174
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
Exercise of warrants
|
2022-03-31 |
| 2022-03-22 | 3056.75 | 未披露 | 定期报告 | 2022-03-22 |
| 2022-03-17 | 3080.94 | 未披露 | 定期报告 | 2022-03-14 |
| 2022-03-17 | 2812.77 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock, redeemable common stock and pre-funded warrants for the purchase of common stock, net of issuance costs of $4.4 million
Issuance of common stock under employee stock purchase plan
Exercise of stock options
Exercise of pre-funded warrants
Vesting of restricted stock units
Repurchase and retirement of redeemable common stock
|
2021-12-31 |
| 2021-12-23 | 2812.73 | 未披露 | 定期报告 | 2021-12-20 |
| 2021-11-04 | 2470.81 | 未披露 | 定期报告 | 2021-10-29 |
| 2021-11-04 | 2470.87 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Repurchase and retirement of redeemable common stock
Vesting of restricted stock units
|
2021-09-30 |
| 2021-08-03 | 2485.16 | 未披露 | 定期报告 | 2021-07-30 |
| 2021-08-03 | 2481.47 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock under employee stock purchase plan
Exercise of prefunded warrants
Vesting of restricted stock units
|
2021-06-30 |
| 2021-06-25 | 2476.66 | 未披露 | 定期报告 | 2021-06-23 |
| 2021-04-20 | 2366.57 | 未披露 | 定期报告 | 2021-04-05 |
| 2021-05-06 | 2342.64 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock, redeemable common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $3.5 million
Exercise of stock options
Exercise of prefunded warrants
|
2021-03-31 |
| 2021-03-19 | 1738.45 | 未披露 | 定期报告 | 2021-03-15 |
| 2021-03-19 | 1630.57 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Exercise of stock options
Issuance of shares under employee stock purchase plan
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
|
2020-12-31 |
| 2020-10-19 | 1628.66 | 未披露 | 定期报告 | 2020-10-14 |
| 2020-11-05 | 1628.66 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of stock options
Vesting of restricted stock units,less shares withheld and retired to satisfy tax obligations
|
2020-09-30 |
| 2020-08-07 | 1617.62 | 未披露 | 定期报告 | 2020-08-03 |
| 2020-08-04 | 1617.62 | 未披露 |
更多>>
from March 31, 2020 to June 30, 2020
Exercise of stock options
Issuance of shares under employee stock purchase plan
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
|
2020-06-30 |
| 2020-04-28 | 1614.23 | 未披露 | 定期报告 | 2020-04-15 |
| 2020-05-07 | 1614.19 | 未披露 |
更多>>
from December 31, 2019 to March 31, 2020
Exercise of stock options
|
2020-03-31 |
| 2020-03-12 | 1613.45 | 未披露 | 定期报告 | 2020-03-06 |
| 2020-03-12 | 1612.89 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Conversion of convertible preferred shares into common stock
Conversion of redeemable common stock into common stock
Exchange of common stock in connection with Merger
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.4 million
Exercise of stock options
Exercise of warrants
|
2019-12-31 |
| 2019-11-29 | 1610.29 | 未披露 | 定期报告 | 2019-11-29 |
| 2019-11-07 | 1245.64 | 未披露 | 定期报告 | 2019-11-04 |
| 2019-11-07 | 1243.62 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Exercise of stock options
|
2019-09-30 |
| 2019-08-07 | 1243.04 | 未披露 | 定期报告 | 2019-08-02 |
| 2019-08-07 | 1242.91 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $931
Exercise of stock options
Exercise of warrants
|
2019-06-30 |
| 2019-05-22 | 1242.08 | 未披露 | 定期报告 | 2019-04-29 |
| 2019-05-15 | 672.45 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Conversion of convertible preferred shares into common stock
Conversion of redeemable common stock into common stock
Exchange of common stock in connection with Merger
Exercise of stock options
|
2019-03-31 |
| 2019-03-14 | 244.06 | 未披露 |
更多>>
Effective at 5:00 p.m. EST on March 13, 2019, the Company effected a 1-for-6 reverse stock split of its common stock (the “Reverse Stock Split”) and changed its name to “X4 Pharmaceuticals, Inc.” Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by X4, which is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases.
|
2019-03-14 |
| 2019-03-11 | 1464.37 | 未披露 | 定期报告 | 2019-03-01 |
| 2019-03-11 | 1457.22 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Exercise of common stock options
Issuance of common stock under employee tock purchase plan
Issuance of restricted common stock
|
2018-12-31 |
| 2018-11-27 | 1431.54 | 未披露 | 定期报告 | 2018-11-27 |
| 2018-08-13 | 1431.54 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-04-23 | 1429.44 | 未披露 | 定期报告 | 2018-03-01 |
| 2018-03-09 | 1429.44 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of Series D redeemable convertible preferred stock, net of issuance costs of $208
Issuance of Series D redeemable convertible preferred stock in connection with the extinguishment of convertible promissory note
Conversion of convertible preferred stock into common stock upon closing of initial public offering
Issuance of common stock upon closing of initial public offering, net of issuance costs of $6,516
Issuance of common stock upon closing of private placement, net of issuance costs of $1,400
|
2017-12-31 |
| 2017-11-17 | 1369.44 | 未披露 |
更多>>
1.Common stock offered in this offering 4,000,000 shares
2.The number of shares of our common stock to be outstanding after this offering, assuming completion of the concurrent private placement, is based on 513,900 shares of our common stock outstanding as of September 30, 2017
3. one-for-3.4130 reverse stock split of our common stock effected on November 3, 2017
|
2017-11-16 |
| 2017-11-06 | 51.39 | 未披露 | 定期报告 | 2017-09-30 |
Common Stock offered 52,844,000 shares by the company
From June 30, 2025 to September 30, 2025
Sale of common stock, net of issuance costs
Vesting of restricted stock units
Exercise of pre-funded warrants
From March 31, 2025 to June 30, 2025
Proceeds from the sale of common stock, less discounts
Issuance of common stock under employee stock purchase plan
Vesting of restricted stock units
a one-for-thirty reverse stock split of the company’s Common Stock
From December 31, 2023 to December 31, 2024
Issuance of common stock under employee stock purchase plan
Vesting of restricted stock units
From June 30, 2024 to September 30, 2024
Vesting of restricted stock units
From March 31, 2024 to June 30, 2024
Issuance of shares of common stock under employee stock purchase plan
Vesting of restricted stock units
From December 31,2022 to December 31,2023
Issuance of common stock, warrants and prefunded warrants for the purchase of common stock, net of issuance costs of $4.6 million
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
Exercise of stock options and warrants
Issuance of shares of common stock under employee stock purchase plan
From June 30, 2023 to September 30, 2023
Exercise of stock options and warrants
Vesting of restricted stock units
From March 31, 2023 to June 30, 2023
Exercise of stock options and warrants
Issuance of shares of common stock under employee stock purchase plan
Issuance of common stock and prefunded warrants in private placement equity transaction, net of issuance costs
Vesting of restricted stock units
From December 31, 2021 to December 31, 2022
Issuance of common stock, warrants and prefunded warrants for the purchase of common stock, net of issuance costs of $4.7 million
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
Exercise of warrants and prefunded warrants
Issuance of shares of common stock under employee stock purchase plan
Common stock offered 52,300,000 shares by the company
From June 30, 2022 to September 30, 2022
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $1,004
Vesting of restricted stock units
1.37,649,086 shares issued on July 6, 2022 as stated in the Purchase Agreement
From March 31, 2022 to June 30, 2022
Issuance of shares of common stock under employee stock purchase plan
Vesting of restricted stock units
From December 31, 2021 to March 31, 2022
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $174
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
Exercise of warrants
From December 31, 2020 to December 31, 2021
Issuance of common stock, redeemable common stock and pre-funded warrants for the purchase of common stock, net of issuance costs of $4.4 million
Issuance of common stock under employee stock purchase plan
Exercise of stock options
Exercise of pre-funded warrants
Vesting of restricted stock units
Repurchase and retirement of redeemable common stock
From June 30, 2021 to September 30, 2021
Repurchase and retirement of redeemable common stock
Vesting of restricted stock units
From March 31, 2021 to June 30, 2021
Issuance of common stock under employee stock purchase plan
Exercise of prefunded warrants
Vesting of restricted stock units
From December 31, 2020 to March 31, 2021
Issuance of common stock, redeemable common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $3.5 million
Exercise of stock options
Exercise of prefunded warrants
from December 31, 2019 to December 31, 2020
Exercise of stock options
Issuance of shares under employee stock purchase plan
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
From June 30, 2020 to September 30, 2020
Exercise of stock options
Vesting of restricted stock units,less shares withheld and retired to satisfy tax obligations
from March 31, 2020 to June 30, 2020
Exercise of stock options
Issuance of shares under employee stock purchase plan
Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations
from December 31, 2019 to March 31, 2020
Exercise of stock options
from December 31, 2018 to December 31, 2019
Conversion of convertible preferred shares into common stock
Conversion of redeemable common stock into common stock
Exchange of common stock in connection with Merger
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.4 million
Exercise of stock options
Exercise of warrants
from June 30, 2019 to September 30, 2019
Exercise of stock options
From March 31, 2019 to June 30, 2019
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $931
Exercise of stock options
Exercise of warrants
from December 31, 2018 to March 31, 2019
Conversion of convertible preferred shares into common stock
Conversion of redeemable common stock into common stock
Exchange of common stock in connection with Merger
Exercise of stock options
Effective at 5:00 p.m. EST on March 13, 2019, the Company effected a 1-for-6 reverse stock split of its common stock (the “Reverse Stock Split”) and changed its name to “X4 Pharmaceuticals, Inc.” Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by X4, which is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases.
from December 31, 2017 to December 31, 2018
Exercise of common stock options
Issuance of common stock under employee tock purchase plan
Issuance of restricted common stock
from December 31, 2016 to December 31, 2017
Issuance of Series D redeemable convertible preferred stock, net of issuance costs of $208
Issuance of Series D redeemable convertible preferred stock in connection with the extinguishment of convertible promissory note
Conversion of convertible preferred stock into common stock upon closing of initial public offering
Issuance of common stock upon closing of initial public offering, net of issuance costs of $6,516
Issuance of common stock upon closing of private placement, net of issuance costs of $1,400
1.Common stock offered in this offering 4,000,000 shares
2.The number of shares of our common stock to be outstanding after this offering, assuming completion of the concurrent private placement, is based on 513,900 shares of our common stock outstanding as of September 30, 2017
3. one-for-3.4130 reverse stock split of our common stock effected on November 3, 2017